Department of Health and Human Services August 2014 – Federal Register Recent Federal Regulation Documents

Results 151 - 200 of 325
Brain-Computer Interface Devices for Patients With Paralysis and Amputation; Public Workshop; Request for Comments
Document Number: 2014-19576
Type: Notice
Date: 2014-08-19
Agency: Food and Drug Administration, Department of Health and Human Services
Acquisition Regulations
Document Number: 2014-19312
Type: Rule
Date: 2014-08-19
Agency: Department of Health and Human Services
The Department of Health and Human Services (HHS) is issuing a final rule to amend its Federal Acquisition Regulation (FAR) Supplementthe HHS Acquisition Regulation (HHSAR)to add two clauses, Patent RightsExceptional Circumstances and, Rights in Data Exceptional Circumstances, and their prescriptions.
Office of the Director, National Institutes of Health; Notice of Meeting
Document Number: 2014-19503
Type: Notice
Date: 2014-08-18
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Environmental Health Sciences; Notice of Closed Meeting
Document Number: 2014-19502
Type: Notice
Date: 2014-08-18
Agency: Department of Health and Human Services, National Institutes of Health
National Center for Complementary & Alternative Medicine; Notice of Meeting
Document Number: 2014-19501
Type: Notice
Date: 2014-08-18
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Nursing Research; Notice of Meeting
Document Number: 2014-19500
Type: Notice
Date: 2014-08-18
Agency: Department of Health and Human Services, National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Document Number: 2014-19499
Type: Notice
Date: 2014-08-18
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Document Number: 2014-19498
Type: Notice
Date: 2014-08-18
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Cancellation of Meeting
Document Number: 2014-19497
Type: Notice
Date: 2014-08-18
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Document Number: 2014-19496
Type: Notice
Date: 2014-08-18
Agency: Department of Health and Human Services
Center for Substance Abuse Prevention; Notice of Meeting
Document Number: 2014-19483
Type: Notice
Date: 2014-08-18
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Applications for New Awards; Preschool Development Grants-Expansion Grants
Document Number: 2014-19427
Type: Notice
Date: 2014-08-18
Agency: Department of Education, Department of Health and Human Services
Applications for New Awards; Preschool Development Grants-Development Grants
Document Number: 2014-19426
Type: Notice
Date: 2014-08-18
Agency: Department of Education, Department of Health and Human Services
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Document Number: 2014-19408
Type: Notice
Date: 2014-08-15
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
NIOSH Current Intelligence Bulletin: Promoting Health and Preventing Disease and Injury through Workplace Tobacco Policies
Document Number: 2014-19384
Type: Notice
Date: 2014-08-15
Agency: Department of Health and Human Services, Centers for Disease Control and Prevention (cdc)
The National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention announces the availability of a draft Current Intelligence Bulletin (CIB) entitled NIOSH Current Intelligence Bulletin: Promoting Health and Preventing Disease and Injury through Workplace Tobacco Policies for public comment. To view the notice and related materials, visit http:// www.regulations.gov and enter CDC-2014-0013 in the search field and click ``Search.'' Public comment period: Comments must be received September 15, 2014.
Final Effect of Designation of a Class of Employees for Addition to the Special Exposure Cohort
Document Number: 2014-19378
Type: Notice
Date: 2014-08-15
Agency: Department of Health and Human Services
HHS gives notice concerning the final effect of the HHS decision to designate a class of employees from the Nuclear Metals Inc. facility in West Concord, Massachusetts, as an addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000.
Pilot Program for Qualification of Medical Device Development Tools
Document Number: 2014-19360
Type: Notice
Date: 2014-08-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is soliciting proposals to participate in a pilot program for Medical Device Development Tools (MDDT) qualification (MDDT Pilot Program). Under the MDDT Pilot Program, FDA intends to work together with developers of tools that meet the criteria for the proposed program, to determine whether certain tools may be developed and qualified in order to facilitate more predictable, efficient, and transparent regulatory evaluation when MDDTs are used to generate valid scientific evidence for medical device premarket applications.
National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings
Document Number: 2014-19321
Type: Notice
Date: 2014-08-15
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting
Document Number: 2014-19320
Type: Notice
Date: 2014-08-15
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings
Document Number: 2014-19319
Type: Notice
Date: 2014-08-15
Agency: Department of Health and Human Services, National Institutes of Health
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Document Number: 2014-19260
Type: Notice
Date: 2014-08-15
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Determination That DRIXORAL (Dexbrompheniramine Maleate; Pseudoephedrine Sulfate) Tablet and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Document Number: 2014-19272
Type: Notice
Date: 2014-08-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
Guidance for Industry on Immunogenicity Assessment for Therapeutic Protein Products; Availability
Document Number: 2014-19267
Type: Notice
Date: 2014-08-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or the Agency) is announcing the availability of a guidance for industry entitled ``Immunogenicity Assessment for Therapeutic Protein Products.'' Therapeutic protein products may elicit immune responses, which may lead to serious or life-threatening adverse events for the patient or loss of efficacy of the product. This guidance is intended to assist manufacturers and clinical investigators in developing a risk-based approach in both the nonclinical and clinical phases of product development that will allow them to evaluate and reduce the likelihood that the immunogenicity of the product will cause harm to patients. This guidance finalizes the draft guidance issued in February 2013.
Revised Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products-Considerations, Content, and Format; Availability
Document Number: 2014-19264
Type: Notice
Date: 2014-08-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of a revised draft guidance for industry entitled ``Clinical Pharmacology Labeling for Human Prescription Drug and Biological ProductsConsiderations, Content, and Format.'' This draft guidance is one of a series of guidance documents intended to assist applicants in complying with FDA regulations on the content and format of labeling for human prescription drug and biological products. The guidance describes the recommended information to include in the Clinical Pharmacology section of labeling that pertains to the safe and effective use of human prescription drug and biological products. This revised draft guidance replaces the 2009 draft guidance for industry entitled ``Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological ProductsContent and Format.''
Draft Guidance for Industry on Best Practices in Developing Proprietary Names for Drugs; Reopening of the Comment Period
Document Number: 2014-19261
Type: Notice
Date: 2014-08-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is reopening the comment period for the draft guidance entitled ``Best Practices in Developing Proprietary Names for Drugs,'' which published in the Federal Register of May 29, 2014 (79 FR 30852). FDA is reopening the comment period in response to several requests for additional time and to allow interested persons more time to submit comments.
Clinical Development of Drugs for the Prevention of Infections Caused by Staphylococcus aureus in the Health Care Setting; Public Workshop
Document Number: 2014-19257
Type: Notice
Date: 2014-08-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing a public workshop regarding the clinical development of drugs for the prevention of serious infections caused by Staphylococcus aureus in the health care setting. This public workshop is intended to provide information for and gain perspective from health care providers, patients and patient advocacy organizations, academia, and industry on various aspects of clinical development of drugs to prevent Staphylococcus aureus infections including the design of clinical trials. The input from this public workshop will help in developing topics for further discussion. Date and Time: The public workshop will be held on September 5, 2014, from 8:30 a.m. to 5 p.m. Location: The public workshop will be held at the DoubleTree by Hilton Hotel Washington DC, 8727 Colesville Rd., Silver Spring, MD 20910. The hotel's phone number is 301-589-5200. Contact Persons: Carole Miller or Lori Benner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6217, Silver Spring, MD 20993-0002, 301- 796-1300. Registration: Registration is free for the public workshop. Interested parties are encouraged to register early. Seating is limited and will be available on a first-come, first-served basis. To register electronically, email registration information (including name, title, firm name, address, telephone, and fax number) to FDASTAPHWORKSHOP@fda.hhs.gov. Onsite registration the day of the workshop will be available, but advanced registration is preferred. Persons without access to the Internet can call 301-796-1300 to register. If you need a sign language interpreter or other special accommodations, please notify Carole Miller or Lori Benner (see Contact Persons) at least 7 days in advance.
Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements; Correction
Document Number: 2014-19255
Type: Notice
Date: 2014-08-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is correcting a final rule entitled ``Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements'' that appeared in the Federal Register of June 10, 2014 (79 FR 33072). The document amended FDA's postmarketing safety reporting regulations for human drug and biological products to require that persons subject to mandatory reporting requirements submit safety reports in an electronic format that FDA can process, review, and archive. The document was published with incorrect information regarding the availability of the International Conference on Harmonization's (ICH) data elements for postmarketing safety reports. The document also published with an incorrect statement regarding the impact of the final rule on small entities. This document corrects those errors.
De Novo Classification Process (Evaluation of Automatic Class III Designation); Draft Guidance for Industry and Food and Drug Administration Staff; Availability
Document Number: 2014-19253
Type: Notice
Date: 2014-08-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled ``De Novo Classification Process (Evaluation of Automatic Class III Designation).'' The purpose of this document is to provide FDA's proposals for guidance to FDA staff and industry on the process for the submission and review of petitions submitted under the Evaluation of Automatic Class III Designation section of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), also known as the de novo classification process. FDA is issuing this draft guidance to provide proposed updated recommendations for efficient interaction with FDA, including what information to submit when seeking a path to market for a novel device via the de novo process. This draft guidance has been revised and is being reissued for comment because the Food and Drug Administration Safety and Innovation Act (FDASIA), which became law on July 9, 2012, amended the FD&C Act to provide for the submission of de novos without a preceding premarket notification (510(k)) submission. This draft guidance is not final nor is it in effect at this time.
Proposed Data Collections Submitted for Public Comment and Recommendations
Document Number: 2014-19245
Type: Notice
Date: 2014-08-14
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food Canning Establishment Registration, Process Filing, and Recordkeeping for Acidified Foods and Thermally Processed Low-Acid Foods in Hermetically Sealed Containers
Document Number: 2014-19241
Type: Notice
Date: 2014-08-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request
Document Number: 2014-19219
Type: Notice
Date: 2014-08-14
Agency: Department of Health and Human Services, Health Resources and Services Administration
In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the Health Resources and Services Administration (HRSA) has submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period.
Advisory Council on Blood Stem Cell Transplantation; Notice of Meeting
Document Number: 2014-19218
Type: Notice
Date: 2014-08-14
Agency: Department of Health and Human Services, Health Resources and Services Administration
Advisory Committee on Breast Cancer in Young Women (ACBCYW)
Document Number: 2014-19202
Type: Notice
Date: 2014-08-14
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Advisory Commission on Childhood Vaccines; Notice of Meeting
Document Number: 2014-19201
Type: Notice
Date: 2014-08-14
Agency: Department of Health and Human Services, Health Resources and Services Administration
Rural Health Services Outreach Program
Document Number: 2014-19200
Type: Notice
Date: 2014-08-14
Agency: Department of Health and Human Services, Health Resources and Services Administration
The Office of Rural Health Policy (ORHP) will provide program expansion supplemental awards to the current Rural Health Services Outreach Program grantees. The program expansion supplemental funds will allow current Outreach grantees to expand outreach and enrollment activities to the rural uninsured for the next Affordable Care Act's (ACA) Health Insurance Marketplace open enrollment period (November 15, 2014-February 15, 2015). In addition, it will help educate the newly insured about the insurance and benefits they can now access as a result of enrolling during the initial Health Insurance Marketplace open enrollment period. The overarching goals of this supplemental funding are to: (1) Increase the number of uninsured educated about their coverage options; (2) increase the number of uninsured enrolled into the Health Insurance Marketplaces or other available sources of insurance, such as Medicaid and the Children's Health Insurance Program; and (3) increase the number of newly insured individuals educated about the benefits and primary care and preventative services to which they now have access.
Centers for Disease Control and Prevention (CDC)/Health Resources and Services Administration (HRSA) Advisory Committee on HIV, Viral Hepatitis, and Sexually Transmitted Disease (STD) Prevention and Treatment
Document Number: 2014-19199
Type: Notice
Date: 2014-08-14
Agency: Department of Health and Human Services, Health Resources and Services Administration
The Health Resources and Services Administration (HRSA) is requesting nominations to fill three vacancies on the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT).
Agency Information Collection Activities: Proposed Collection: Public Comment Request
Document Number: 2014-19198
Type: Notice
Date: 2014-08-14
Agency: Department of Health and Human Services, Health Resources and Services Administration
In compliance with the requirement for opportunity for public comment on proposed data collection projects (Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995), the Health Resources and Services Administration (HRSA) announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
Center for Mental Health Services; Notice of Meeting
Document Number: 2014-19182
Type: Notice
Date: 2014-08-14
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Meeting
Document Number: 2014-19147
Type: Notice
Date: 2014-08-13
Agency: Department of Health and Human Services, National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Notice of Meeting
Document Number: 2014-19146
Type: Notice
Date: 2014-08-13
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Document Number: 2014-19145
Type: Notice
Date: 2014-08-13
Agency: Department of Health and Human Services, National Institutes of Health
Prospective Grant of Exclusive License: Identification of Non-Invasive Biomarkers of Coordinate Metabolic Reprogramming in Colorectal Tumor
Document Number: 2014-19144
Type: Notice
Date: 2014-08-13
Agency: Department of Health and Human Services, National Institutes of Health
This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to Cary Pharmaceuticals, Inc. (``Cary'') located in Great Falls, VA, USA.
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: 2014-19120
Type: Notice
Date: 2014-08-13
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Multi-Agency Informational Meeting Concerning Compliance With the Import Permit Program; Public Webcast
Document Number: 2014-19114
Type: Notice
Date: 2014-08-13
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The Centers for Disease Control and Prevention (CDC) located within the United States Department of Health and Human Services (HHS) announces a public webcast for all individuals who apply for permits to import (1) infectious biological agents, infectious substances, or vectors known to transfer or that are capable of transferring an infectious biological agent to a human; and (2) import items that contain or may contain dangerous agricultural pests and diseases. The purpose of the webcast is to provide guidance related to the import permit program.
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: 2014-19104
Type: Notice
Date: 2014-08-13
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Meeting of the National Vaccine Advisory Committee
Document Number: 2014-19046
Type: Notice
Date: 2014-08-12
Agency: Department of Health and Human Services
As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the National Vaccine Advisory Committee (NVAC) will hold a meeting September 9-10, 2014. The meeting is open to the public. However, pre-registration is required for both public attendance and public comment. Individuals who wish to attend the meeting and/or participate in the public comment session should register at http://www.hhs.gov/nvpo/nvac. Participants may also register by emailing nvpo@hhs.gov or by calling 202-690-5566 to provide your name, organization, and email address.
Agency Information Collection Activities: Proposed Collection; Extension of Comment Period
Document Number: 2014-19027
Type: Notice
Date: 2014-08-12
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
This notice extends the comment period for a 60-day notice request for proposed information collection request associated with the notice [Document Identifier: CMS- 10305] entitled ``Medicare Part C and Part D Data Validation'' that was published in the June 13, 2014 (79 FR 33927) Federal Register. The comment period for the information collection request, which would have ended on August 12, 2014, is extended to August 26, 2014.
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus
Document Number: 2014-19026
Type: Notice
Date: 2014-08-12
Agency: Department of Health and Human Services
The Secretary of Health and Human Services (HHS) is issuing this notice pursuant to section 564 of the Federal Food, Drug, and Cosmetic (FD&C) Act, 21 U.S.C. 360bbb-3. On September 22, 2006, then Secretary of Homeland Security, Michael Chertoff, determined pursuant to section 319F-2 of the Public Health Service Act, 42 U.S.C. 247d-6b, that the Ebola virus presents a material threat against the United States population sufficient to affect national security. On the basis of this determination, on August 4, 2014 the Secretary declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection of Ebola virus pursuant to section 564 of the FD&C Act, subject to the terms of any authorization issued under that section.
Agency Information Collection Activities; Proposed Collection; Comment Request; Food Allergen Labeling and Reporting
Document Number: 2014-19004
Type: Notice
Date: 2014-08-12
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or we) is announcing an opportunity for public comment on our proposed collection of certain information. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice invites comments on the information collection provisions of the labeling requirements for major food allergens in the Federal Food, Drug, and Cosmetic Act (the FD&C Act) and the information collection provisions of the draft guidance entitled, ``Draft Guidance for Industry: Food Allergen Labeling Exemption Petitions and Notifications.''